Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Bristol-Myers Squibb (BMS)

Status

Completed

Conditions

Advanced Melanoma

Treatments

Biological: Nivolumab + Ipilimumab

Biological: Immunotherapy monotherapy

Drug: BRAF/MEK inhibitors

Biological: Nivolumab + Relatlimab

Study type

Observational

Funder types

Industry

Identifiers

NCT07079644

CA224-1098

Details and patient eligibility

About

The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy

Enrollment

678 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants in the advanced melanoma cohort
- Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either at initial diagnosis or via local or distant recurrence, and at least two clinic encounters evident in the database
Participants receiving Nivolumab + Relatlimab between March 18, 2022 and September 30, 2024 or other therapies (Nivolumab + Ipilimumab, immunotherapy monotherapy, BRAF/MEK inhibitors) between March 18, 2022 and November 30, 2024 (or date of the most recent data cut off)
Participants ≥18 years old on index date
Participants with ≥1 month of medical data after the index date (inclusive), unless patient died within this period

Exclusion criteria

Participants with diagnosis of other primary cancers prior to the index date
Participants receiving medication in a clinical trial at any time prior to, on or after index date